Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
NextGen Sciences launches multiple protein plasma oncology biomarker assay. Hope this'll get things going
Booooom - ish - Up over 10% and a promising future. One for the future.
NextGen Sciences completes biomarker business refocus Ann Arbor, Michigan, US, and London, UK, 9 March 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has completed a commercial reorganization. The restructuring, which is accompanied by new management appointments, is expected to help the company execute its strategy of becoming a leading player in the growing oncology and central nervous system (CNS) biomarker markets. Targeting these therapeutic areas, two new biomarker assay products are expected to be launched in the first half of this year. Key appointments include Dr Neal Siegel as Director of Assay Development, a new position. He joins from Sword Diagnostics Inc and prior to that the US healthcare company Abbott Laboratories, and will lead assay delivery, validation and quality control. Glenn Barney, formerly of US company Decision Biomarkers, becomes Vice-President of Business Development, and will be responsible for driving sales growth across all products, as well as overseeing marketing. Hiroshi Saito joins from Optiem LLC, an internet and digital marketing agency, as Director of Marketing, working closely with Glenn Barney. Growth of the biomarker market is being driven by a variety of factors, including increased recognition of their utility in clinical trials for patient stratification and understanding of pharmacodynamics (the effect and mechanism of action of a drug in the body). Klaus Rosenau, Chairman and CEO of NextGen Group, commented: "NextGen Sciences' reorganization brings an increased commercial focus to our biomarker business, with the new appointees bringing extensive technical and commercial expertise. The next step is expected to be the launch of a human plasma assay targeting several oncology disease areas, and a human cerebrospinal fluid assay for CNS disorders, in the first half of this year. This will help us generate value in this growing market via our quality products and services, and increased partnering with pharmaceutical, biotechnology and diagnostics companies. We believe that our increasing profile will be beneficial to our long-term aim of bringing complementary technologies into the NextGen Group".
Looks like SAR was the next SAR - up 120% today
Seemed to me to be a case of no direction, no staff, no plan Hope your both right though.
waiting for the next pump n dump.
0.35 0.38 oh well that'll teach me to jump in on a rise with no news.......
Yep...and in classicform I bought 'em. Now I'll have to wait to get my dosh back before I sell....bit like PYC, PXS and too many others. One day I'll buy 'em and they'll go UP!
I think the damage is done after that RNS and will rise from next week due to other interests.
worth a punt at this price???
Try this http://www.thinkbox.tv/ if the below doesn't work.
Here's an advert by thinkbox about advertising....for my sake will the powers at be watch it and take note! oh it's also a funny vid. http://bit.ly/clrVce
Only been offered 8p to sell
Got to laugh..on tmmg's web site..'(we) help to make our client's brands famous and achieve sustainable financial performance. Together we make so much more.'....If only they would do that for themselves! would help if everytime they get new clients they release an RNS.
Sorry, I thought for a moment that i heard something, must have been tumbleweed, where's the light switch? see you all at Christmas.
I'll switch the lights back on...
I'll switch the lights off.